Aprea Therapeutics

Aprea Therapeutics is a leader in DDR-targeted solutions, developing novel cancer therapeutics that target DNA damage response pathways.

Aprea Therapeutics develops APR-1051, its lead WEE1 inhibitor in active clinical trials, alongside ATRN-119 and other DDR-targeted pipeline programs.

This Privacy Policy describes how Aprea Therapeutics collects, uses, discloses, and otherwise process personal information.

Aprea Therapeutics CEO outlines the company’s 2025 pipeline advancements and strategic priorities for 2026 in a letter to shareholders. The update covers key clinical-stage programs and development milestones, emphasizing progress in therapeutic candidates. Leadership highlights operational and financial planning to support ongoing research efforts.

Dec 2025GlobeNewswireNews article

Aprea Therapeutics partners with MD Anderson Cancer Center to investigate its experimental compound **APR-1051** as a potential therapy for **head and neck squamous cell carcinoma (HNSCC)**. The collaboration aims to evaluate the drug’s efficacy in preclinical or early-stage clinical studies targeting this aggressive cancer type. Aprea, a clinical-stage biopharmaceutical company, develops oncology-focused treatments, including immunotherapies and small-molecule inhibitors.

Mar 2025GlobeNewswireNews article

Aprea Therapeutics refocuses its intellectual property portfolio to advance DNA Damage Response (DDR) cancer therapeutics. The company specializes in clinical-stage drug development targeting DDR pathways, which play a critical role in tumor suppression. This strategic shift aims to strengthen its pipeline in precision oncology by leveraging proprietary assets in the field.

Feb 2025GlobeNewswireNews article

Aprea Therapeutics presents research at the EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics. The company highlights its clinical-stage work in oncology drug development. Presentations focus on molecular targets and therapeutic approaches for cancer treatments.

Oct 2024GlobeNewswireNews article